Crohn's Disease, Spondyloarthritis
Conditions
Brief summary
In patients with Crohn's Disease, symptoms of inflammatory back pain (IBP) precede changes on plain X-rays by years, and MRI changes of axial inflammation precede development of X-ray changes. Sacroiliitis on MRI without x-ray changes (i.e.Non radiographic SpA) is a valid diagnostic criterion for Spondyloarthritis (SpA) and leads to earlier diagnosis of SpA in patients with IBP. It is unclear when MRI changes occur, and if they precede clinical symptoms of IBP. There are reports of asymptomatic sacroiliitis noted on MRI in Crohn's patients. This is important, as MRI evidence of inflammation may be the first sign of incipient SpA. Inflammation in other regions of the axial skeleton in SpA patients has also been documented, but its significance is unknown. The prospect of undiagnosed and untreated inflammation is concerning, as it can lead to significant morbidity. Moreover, relationship between MRI evidence of axial inflammation-likely a proxy for systemic inflammation- and patient reported outcomes (e.g. ASDAS-CRP= Ankylosing Spondylitis Disease Activity Score- C reactive protein, BASDAI= Bath Ankylosing Spondylitis Disease Activity Index, SF-12 = Short Form- 12, HBI= Hervey Bradshaw Index and PROMIS-29= Patient Reported Outcome Measurement Information System-29), has not been reported. Recent unpublished data from Dr. Longman's lab (collaborator) suggest a distinct intestinal dysbiosis in Crohn's associated SpA. But relationship between this microbiome and MRI changes is yet to be determined. Identifying inflammation earlier on MRI- in the absence of clinical symptoms will provide an opportunity to intervene early with available therapies, such as- biologics etc. Asymptomatic MRI changes could be a marker of underlying systemic inflammation- which is a risk factor for poor outcomes in Crohn's associated SpA. Studying association between whole spine MRI changes with patient reported outcomes) may facilitate informed clinical decision making to initiate targeted therapy to prevent progression of structural damage. Understanding microbial dysregulation in this population, and correlation with MRI changes, could lead to development of therapy targeted to restore intestinal symbiosis.
Detailed description
IMAGING AND CROHN'S ASSOCIATED SpA: Crohn's disease (CD) is the most common type of inflammatory bowel disease (IBD). It affects an estimated 0.7 million patients in United States and is responsible for 0.2 million hospitalizations each year.1 Although the gastrointestinal tract is the primary site of inflammation, inflammatory arthritis (both peripheral and axial) can affect between 12.8-23% of patients with Crohn's Disease2,3, and axial SpA alone has been reported to effect 6.7% to 18% of Crohn's patients.4 However, in 2 recent studies5,6, radiological sacroiliitis was reported to be present in 27% and 52% in IBD patients. MRI changes of inflammation precede radiological sacroiliitis by years but it is not clear when this occurs. Presence of damage on x-ray in asymptomatic patients may suggest that Crohn's associated axial SpA could be underdiagnosed. Since Crohn's associated SpA often affects younger patients, undertreatment or missed diagnoses could have a significant impact on health related quality of life (HR-QoL) and disability during prime wage earning and child rearing years.7 Non-radiographic axial spondyloarthritis is a term used to describe patients with symptomatic SpA who do not have findings on plain x-rays. These patients can have identical symptoms to those with radiographic evidence of cartilage loss and erosions, and anti-TNF (anti-Tumor Necrosis Factor) therapy has been shown to be effective in those with non-radiographic SpA.8 These patients are a clinically relevant subgroup, as 20% of patients with only MRI evidence of sacroiliitis will progress to non-reversible radiographic SpA over two years.9 Therefore, MRI evidence of sacroiliitis, in conjunction with inflammatory back pain is now sufficient to diagnosis SpA. In fact, MRI imaging is a standard component of current SpA diagnostic criteria, (ASAS: Assessment of SpondyloArthritis International Society),10 and MRI changes of sacroiliitis are routinely used to identify SpA patients for clinical trials.11 However, despite these new definitions there is a deficiency of published research evaluating the clinical significance of MRI findings in patients with Crohn's disease. Of all the SpA-associated diseases, Crohn's-associated SpA has a particularly high burden of extra-articular inflammation. Studies suggest only half to two thirds of patients with CT or MRI evidence of inflammation have symptoms of inflammatory back pain.1,12 This suggests that in Crohn's disease, MRI imaging biomarkers may be identifying early disease, analogous to the way that ultrasound can identify subclinical rheumatoid arthritis.13 We therefore hypothesize that in a mixed cohort of Crohn's patients with and without inflammatory back pain, MRI imaging biomarkers will correlate with measures of health status which reflect systemic inflammatory burden, (i.e. BASDAI, SF-12) independent of symptoms of inflammatory back pain. MRI IMAGING BIOMARKERS: A POTENTIAL CARDIOVASCULAR RISK FACTOR? The observed discordance between axial inflammation seen on MRI and inflammatory back pain raises a particularly intriguing clinical question: could Crohn's patients with imaging evidence of axial inflammation but without axial symptoms potentially benefit from therapy? It is very well established that in rheumatoid arthritis and psoriatic arthritis, systemic inflammation is associated with myocardial infarction, stroke and death, and that treating inflammation improves cardiovascular outcomes.14,15. Recent population based study from Europe and Canada showed increased risk of cardiovascular mortality in patients with Ankylosing Spondylitis.16,17 Despite clear evidence that cardiovascular risk is increased in SpA, how to quantify the increased risk is not straightforward. There is no consistently reliable marker of systemic inflammation in these patients; sedimentation rate (ESR) and C-reactive protein (CRP) may not always reflect ongoing inflammation, especially in patients with non-radiographic axial SpA9. Therefore, accurately measuring the inflammatory burden in Crohn's patients, regardless of musculoskeletal symptoms, is an important area for future research. Initiation of earlier targeted therapy to decrease inflammation may not only prevent incident Crohn's associated SpA, progression of prevalent SpA, with concurrent improvements in HRQoL, but may also improve cardiovascular morbidity and mortality. In addition, although sacroiliitis is the primary axial feature in SpA, there is increasing evidence that there can also be spinal involvement even in the absence of SI joint inflammation. Recent studies suggest that spinal inflammation can occur in up to one-third of nonradiographic SpA patients with \<5 years of disease duration.18 This could be an important early imaging inflammatory biomarker. To our knowledge there are no published studies evaluating spinal and SI joint MRI imaging biomarkers in Crohn's associated SpA. THE MICROBIOME: A CORRELATE OF INFLAMMATION IN CROHN'S DISEASE? The etiopathogenesis of Crohn's Disease-associated SpA remains a puzzle. As with other autoimmune diseases, interplay between genetic factors such as HLA B27 (Human Leukocyte Antigen- B27) and environmental factors likely play a role. The joint symptoms of SpA are not consistently correlated with bowel disease flares.19 Intestinal microbiota plays a critical role in evolution of our entire immune system, since axenic laboratory animals (germfree animals raised in sterile environment) were noted to have partial restoration of T cell population when these animals are colonized with filamentous bacteria. A symbiotic relationship between the main bacterial phyla is necessary for proper functioning of immune system, since notable alterations in the intestinal microbiome (i.e. dysbiosis) have been suggested in various autoimmune diseases. Reduction in taxa-diversity (such as, enterobacteriaceae, Bacteroidales and Clostridiales) and expansion of certain phyla in the intestine have been recently reported in a large cohort of new onset treatment-naïve Crohn's disease (CD) patients.20 In addition, Dr. Longman's lab has shown that the expansion of immunologically relevant Enterobacteriaceae correlates with Crohn's related SpA among a mixed group of patients with Crohn's and ulcerative colitis, (in press). However, while these are exciting data, SpA cases were identified using a non-validated clinical diagnosis, without systematic rheumatology evaluation and no imaging studies. This will be first study evaluating the microbiome in a carefully phenotyped cohort of Crohn's associated SpA, who will also have detailed MRI imaging.
Interventions
OTHERNo intervention
No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
Sponsors
Weill Medical College of Cornell University
Hospital for Special Surgery, New York
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with biopsy proven Crohn's Disease 2. 50% patients with inflammatory back pain and 50% without inflammatory back pain. 3. Age 18 years and above 4. English Speaking patients only
Exclusion criteria
1. History of psoriasis, other inflammatory arthritis 2. No exposure to biologic agent within the past six months (except Vedolizumab, which exerts its effect locally) 2\. Contraindication to MRI 3\. History of malignancy \<5 years in remission, (except for non-melanomatous skin cancer). 4\. Non English speaking 5\. Unable to comply with study protocol. 6\. Critically or terminally ill patients 7\. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With MRI Positivity- Global Assessment Positive | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. MRI was considered positive for presence of sacroiliitis if it met global evaluation, based on the reader's overall evaluation of presence or absence of sacroiliitis by taking into account the contextual signature of both active and structural SIJ lesions. For analysis, MRI positivity for sacroiliitis was defined based on majority-of-readers agreement (≥2 out of 3). |
| Number of Participants With MRI Positivity- ASAS Positive | one study visit | Assessment of SpondyloArthritis international Society. Subjects are positive if they fulfill 4 out of following 5 back pain parameters: onset of symptoms \<40 years of age, insidious onset of pain, nocturnal pain, improvement with exercise and no improvement with rest. |
| Number of Participants With MRI Positivity- SPACE Positive | one study visit | SpondyloArthritis Caught Early. Positivity based on presence of erosions and fat metaplasia. |
| Number of Participants With MRI Positivity- Morpho Positive | one study visit | Positivity based on presence of bone marrow edema (BME) and/or erosion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bath Ankylosing Spondylitis Metrology Index (BASMI) | one study visit | The scale of the BASMI ranges from 0 to 10, where 0 is no mobility limitation and 10 is a very severe limitation. |
| Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP) | one study visit | Ankylosing Spondylitis Disease Activity Index C-reactive protein. Higher score indicates worse symptoms. ASDAS-CRP = 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1) |
| CRP (C-reactive Protein) | one study visit | Peripheral blood was collected for measurement of CRP. |
| Duration of Crohn's Disease for Participants | one study visit | — |
| Number of Participants Using Vedolizumab for Crohn's Disease | one study visit | — |
| Number of Participants With a Past History of Biologic Use for Crohn's Disease | one study visit | — |
| Number of Participants Who Have Had Surgery Related to Crohn's Disease | one study visit | — |
| Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) | one study visit | HBI consists of five parameters, which are all clinical. These parameters are: patient well-being (previous day). abdominal pain (previous day), number of liquid or soft stools (previous day), abdominal mass, and complications. Patient well-being is scored with: 0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible. Abdominal pain is scored as: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Abdominal mass is scored as: 0 = none, 1 = dubious, 2 = definite, 3 = definite and tender. Complications can be answered with No (0 points) or by choosing from a list, with each selection being 1 point. The list is: arthralgia, uveitis, erythema nodosum, aphthous ulcer, pyoderma gangrenosum, anal fissures, appearance of a new fistula, abscess. Calculation formula: sum of the scores of all 5 parameters. \< 5 remission 5 - 7 mild activity 8 - 16 moderate activity \> 16 severe activity |
| Number of Participants With Inflammatory Back Pain | one study visit | — |
| Number of Participants With Current Enthesitis | one study visit | — |
| Number of Participants With a History of Uveitis | one study visit | — |
| Number of Participants With a History of Dactylitis | one study visit | — |
| Number of Participants With HLA-B27 (Human Leukocyte Antigen B-27) | one study visit | — |
| Duration of Crohn's Disease | one study visit | — |
| Number of Participants With a Prior History of Biologic Use for Crohn's Disease | one study visit | — |
| Interleukin 2 | one study visit | Concentration of IL-2 in peripheral blood of participants. |
| Interleukin 4 | one study visit | Concentration of IL-4 in peripheral blood of participants. |
| Interleukin 5 | one study visit | Concentration of IL-5 in peripheral blood of participants. |
| Interleukin 6 | one study visit | Concentration of IL-6 in peripheral blood of participants. |
| Interleukin 9 | one study visit | Concentration of IL-9 in peripheral blood of participants. |
| Interleukin 10 | one study visit | Concentration of IL-10 in peripheral blood of participants. |
| Interleukin 13 | one study visit | Concentration of IL-13 in peripheral blood of participants. |
| Interleukin 12-23 | one study visit | Concentration of IL 12-23 in peripheral blood of participants. |
| Interleukin 17A | one study visit | Concentration of IL-17A in peripheral blood of participants. |
| Interleukin 17F | one study visit | Concentration of IL-17F in peripheral blood of participants. |
| Interleukin 21 | one study visit | Concentration of IL-21 in peripheral blood of participants. |
| Interleukin 22 | one study visit | Concentration of IL-22 in peripheral blood of participants. |
| Interferon-γ | one study visit | Concentration of INFγ in peripheral blood of participants. |
| TNF-α (Tumor Necrosis Factor) | one study visit | Concentration of TNF-α in peripheral blood of participants. |
| Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. |
| Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. |
| Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With Axial Spondyloarthritis Based on European Spondyloarthropathy Study Group (ESSG) Guidelines | one study visit | Assessment of SpondyloArthritis international Society criteria was utilized to define inflammatory back pain. |
| Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | one study visit | MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers. |
| Number of Participants With Current Peripheral Arthritis | one study visit | — |
| Number of Participants With a History of Peripheral Arthritis | one study visit | — |
| Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | one study visit | Minimum 0. Maximum 10. A score of 0 = none (no symptoms), and a score of 10 = very severe symptoms. |
Countries
United States
Participant flow
Recruitment details
Patients were identified by physicians in the study at outpatient IBD clinics at Cornell during scheduled visits and through review of medical records. Gastroenterologists at the IBD clinic and HSS rheumatologists were contacted and asked about potential patients. Flyers were placed in patient rooms so patients could express interest in study. We approached potential subjects via postal and/or email addresses and sent survey questionnaire to determine eligibility. Recruitment done 4/2016-5/2017.
Participants by arm
| Arm | Count |
|---|---|
| Adult Subjects With Crohn's Disease These were consecutive subjects prospectively identified and enrolled from an outpatient clinic of Jill Roberts Center for Inflammatory Bowel Disease (IBD) at a tertiary care academic medical center. Subjects between 18 and 65 were enrolled from April 2016 through May 2017. All subjects met clinical, pathological or radiological criteria for CD. Patients with ulcerative colitis, indeterminate colitis, other inflammatory arthritis (eg, rheumatoid arthritis, systemic lupus erythematosus, psoriatic or reactive arthritis), co-existent autoimmune diseases (eg, celiac disease, Behçet's disease) or skin psoriasis were excluded. All subjects were either biologic naïve or had been off systemic biologics \>6 months prior to enrollment and could remain on non-biologic CD therapy (eg, methotrexate, sulfasalazine, azathioprine or 6-mercaptopurine). Patients could also be on vedolizumab, an antagonist of α4β7 integrin in the intestinal epithelium which has no established efficacy in extra-intestinal manifestations of CD. Other exclusions included malignancy less than 5 years in remission (except for non-melanomatous skin cancer) or having a contraindication to MRI. | 33 |
| Total | 33 |
Baseline characteristics
| Characteristic | Adult Subjects With Crohn's Disease |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 33 Participants |
| Age, Continuous | 36.4 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 25 Participants |
| Region of Enrollment United States | 33 participants |
| Sex: Female, Male Female | 25 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 33 |
| other Total, other adverse events | 0 / 33 |
| serious Total, serious adverse events | 0 / 33 |
Outcome results
Primary
Number of Participants With MRI Positivity- ASAS Positive
Assessment of SpondyloArthritis international Society. Subjects are positive if they fulfill 4 out of following 5 back pain parameters: onset of symptoms \<40 years of age, insidious onset of pain, nocturnal pain, improvement with exercise and no improvement with rest.
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With MRI Positivity- ASAS Positive | 4 Participants |
| No Back Pain | Number of Participants With MRI Positivity- ASAS Positive | 2 Participants |
Primary
Number of Participants With MRI Positivity- Global Assessment Positive
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. MRI was considered positive for presence of sacroiliitis if it met global evaluation, based on the reader's overall evaluation of presence or absence of sacroiliitis by taking into account the contextual signature of both active and structural SIJ lesions. For analysis, MRI positivity for sacroiliitis was defined based on majority-of-readers agreement (≥2 out of 3).
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With MRI Positivity- Global Assessment Positive | 4 Participants |
| No Back Pain | Number of Participants With MRI Positivity- Global Assessment Positive | 0 Participants |
Primary
Number of Participants With MRI Positivity- Morpho Positive
Positivity based on presence of bone marrow edema (BME) and/or erosion.
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With MRI Positivity- Morpho Positive | 5 Participants |
| No Back Pain | Number of Participants With MRI Positivity- Morpho Positive | 1 Participants |
Primary
Number of Participants With MRI Positivity- SPACE Positive
SpondyloArthritis Caught Early. Positivity based on presence of erosions and fat metaplasia.
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With MRI Positivity- SPACE Positive | 0 Participants |
| No Back Pain | Number of Participants With MRI Positivity- SPACE Positive | 0 Participants |
Secondary
Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP)
Ankylosing Spondylitis Disease Activity Index C-reactive protein. Higher score indicates worse symptoms. ASDAS-CRP = 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1)
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP) | 3.1 score on a scale | Standard Deviation 0.9 |
| No Back Pain | Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP) | 2.1 score on a scale | Standard Deviation 0.9 |
Secondary
Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP)
A higher score indicates worse symptoms. ASDAS-CRP = 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1)
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP) | 3.3 score on a scale | Standard Deviation 0.4 |
| No Back Pain | Ankylosing Spondylitis Disease Activity Index C-reactive Protein (ASDAS-CRP) | 2.5 score on a scale | Standard Deviation 1.2 |
Secondary
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Minimum 0. Maximum 10. A score of 0 = none (no symptoms), and a score of 10 = very severe symptoms.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | 5.3 score on a scale | Standard Deviation 1.8 |
| No Back Pain | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | 2.4 score on a scale | Standard Deviation 1.6 |
Secondary
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Minimum 0. Maximum 10. A score of 0 = none (no symptoms), and a score of 10 = very severe symptoms.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | 4.3 score on a scale | Standard Deviation 1.7 |
| No Back Pain | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | 4.2 score on a scale | Standard Deviation 2.4 |
Secondary
Bath Ankylosing Spondylitis Metrology Index (BASMI)
The scale of the BASMI ranges from 0 to 10, where 0 is no mobility limitation and 10 is a very severe limitation.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Bath Ankylosing Spondylitis Metrology Index (BASMI) | 4.1 score on a scale | Standard Deviation 0.7 |
| No Back Pain | Bath Ankylosing Spondylitis Metrology Index (BASMI) | 2.4 score on a scale | Standard Deviation 0.8 |
Secondary
Bath Ankylosing Spondylitis Metrology Index (BASMI)
The scale of the BASMI ranges from 0 to 10, where 0 is no mobility limitation and 10 is a very severe limitation.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Bath Ankylosing Spondylitis Metrology Index (BASMI) | 2.9 score on a scale | Standard Deviation 0.9 |
| No Back Pain | Bath Ankylosing Spondylitis Metrology Index (BASMI) | 2.1 score on a scale | Standard Deviation 0.9 |
Secondary
Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score)
HBI consists of five parameters, which are all clinical. These parameters are: patient well-being (previous day). abdominal pain (previous day), number of liquid or soft stools (previous day), abdominal mass, and complications. Patient well-being is scored with: 0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible. Abdominal pain is scored as: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Abdominal mass is scored as: 0 = none, 1 = dubious, 2 = definite, 3 = definite and tender. Complications can be answered with No (0 points) or by choosing from a list, with each selection being 1 point. The list is: arthralgia, uveitis, erythema nodosum, aphthous ulcer, pyoderma gangrenosum, anal fissures, appearance of a new fistula, abscess. Calculation formula: sum of the scores of all 5 parameters. \< 5 remission 5 - 7 mild activity 8 - 16 moderate activity \> 16 severe activity
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) | 7.8 score on a scale | Standard Deviation 4.9 |
| No Back Pain | Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) | 8.3 score on a scale | Standard Deviation 4.5 |
Secondary
Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score)
HBI consists of five parameters, which are all clinical. These parameters are: patient well-being (previous day). abdominal pain (previous day), number of liquid or soft stools (previous day), abdominal mass, and complications. Patient well-being is scored with: 0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible. Abdominal pain is scored as: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Abdominal mass is scored as: 0 = none, 1 = dubious, 2 = definite, 3 = definite and tender. Complications can be answered with No (0 points) or by choosing from a list, with each selection being 1 point. The list is: arthralgia, uveitis, erythema nodosum, aphthous ulcer, pyoderma gangrenosum, anal fissures, appearance of a new fistula, abscess. Calculation formula: sum of the scores of all 5 parameters. \< 5 remission 5 - 7 mild activity 8 - 16 moderate activity \> 16 severe activity
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) | 9.1 score on a scale | Standard Deviation 4.9 |
| No Back Pain | Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) | 6.9 score on a scale | Standard Deviation 3.7 |
Secondary
CRP (C-reactive Protein)
Peripheral blood was collected for measurement of CRP.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | CRP (C-reactive Protein) | 2.6 mg/L | Standard Deviation 3 |
| No Back Pain | CRP (C-reactive Protein) | 1.5 mg/L | Standard Deviation 2.6 |
Secondary
CRP (C-reactive Protein)
Peripheral blood was collected for measurement of CRP.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | CRP (C-reactive Protein) | 1.6 mg/L | Standard Deviation 2 |
| No Back Pain | CRP (C-reactive Protein) | 1.7 mg/L | Standard Deviation 3.3 |
Secondary
Duration of Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Duration of Crohn's Disease | 17.9 years | Standard Deviation 3.8 |
| No Back Pain | Duration of Crohn's Disease | 12.2 years | Standard Deviation 8.7 |
Secondary
Duration of Crohn's Disease for Participants
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Duration of Crohn's Disease for Participants | 11.9 years | Standard Deviation 6.7 |
| No Back Pain | Duration of Crohn's Disease for Participants | 14.2 years | Standard Deviation 10.5 |
Secondary
Interferon-γ
Concentration of INFγ in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interferon-γ | 75.7 pg/mL | Standard Deviation 31 |
| No Back Pain | Interferon-γ | 79.0 pg/mL | Standard Deviation 28.8 |
Secondary
Interleukin 10
Concentration of IL-10 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 10 | 31.0 pg/mL | Standard Deviation 59.3 |
| No Back Pain | Interleukin 10 | 6.5 pg/mL | Standard Deviation 1.8 |
Secondary
Interleukin 12-23
Concentration of IL 12-23 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 12-23 | 214.0 pg/mL | Standard Deviation 159.5 |
| No Back Pain | Interleukin 12-23 | 259.1 pg/mL | Standard Deviation 227.7 |
Secondary
Interleukin 13
Concentration of IL-13 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 13 | 8.9 pg/mL | Standard Deviation 6.3 |
| No Back Pain | Interleukin 13 | 8.9 pg/mL | Standard Deviation 4.4 |
Secondary
Interleukin 17A
Concentration of IL-17A in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 17A | 25.3 pg/mL | Standard Deviation 13.1 |
| No Back Pain | Interleukin 17A | 21.1 pg/mL | Standard Deviation 10.5 |
Secondary
Interleukin 17F
Concentration of IL-17F in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 17F | 4.8 pg/mL | Standard Deviation 2.2 |
| No Back Pain | Interleukin 17F | 3.8 pg/mL | Standard Deviation 3.5 |
Secondary
Interleukin 2
Concentration of IL-2 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 2 | 4.7 pg/mL | Standard Deviation 2 |
| No Back Pain | Interleukin 2 | 5.6 pg/mL | Standard Deviation 7.8 |
Secondary
Interleukin 21
Concentration of IL-21 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 21 | 19.8 pg/mL | Standard Deviation 36.2 |
| No Back Pain | Interleukin 21 | 40.0 pg/mL | Standard Deviation 43.2 |
Secondary
Interleukin 22
Concentration of IL-22 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 22 | 15.2 pg/mL | Standard Deviation 7.1 |
| No Back Pain | Interleukin 22 | 16.7 pg/mL | Standard Deviation 11.2 |
Secondary
Interleukin 4
Concentration of IL-4 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 4 | 3.5 pg/mL | Standard Deviation 1.6 |
| No Back Pain | Interleukin 4 | 5.7 pg/mL | Standard Deviation 4.6 |
Secondary
Interleukin 5
Concentration of IL-5 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 5 | 3.7 pg/mL | Standard Deviation 0 |
| No Back Pain | Interleukin 5 | 3.8 pg/mL | Standard Deviation 0.1 |
Secondary
Interleukin 6
Concentration of IL-6 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 6 | 6.2 pg/mL | Standard Deviation 7.2 |
| No Back Pain | Interleukin 6 | 5.1 pg/mL | Standard Deviation 6.9 |
Secondary
Interleukin 9
Concentration of IL-9 in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Interleukin 9 | 2.4 pg/mL | Standard Deviation 1.5 |
| No Back Pain | Interleukin 9 | 1.9 pg/mL | Standard Deviation 0.9 |
Secondary
Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0.86 Number of Quadrants Affected per Person | Standard Deviation 1.45 |
| No Back Pain | Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0.05 Number of Quadrants Affected per Person | Standard Deviation 0.15 |
| Fat Metaplasia | Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0.98 Number of Quadrants Affected per Person | Standard Deviation 3.55 |
| Backfill | Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0.04 Number of Quadrants Affected per Person | Standard Deviation 0.23 |
| Ankylosis | Mean Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 1.02 Number of Quadrants Affected per Person | Standard Deviation 3.45 |
Secondary
Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant.
Time frame: one study visit
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Any Back Pain | Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0 Number of Quadrants Affected per Person |
| No Back Pain | Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0 Number of Quadrants Affected per Person |
| Fat Metaplasia | Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0 Number of Quadrants Affected per Person |
| Backfill | Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0 Number of Quadrants Affected per Person |
| Ankylosis | Median Number of Sacroiliac Joint (SIJ) Quadrants Affected by BME or Structural Lesions for Each Participant | 0 Number of Quadrants Affected per Person |
Secondary
Number of Participants Using Vedolizumab for Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants Using Vedolizumab for Crohn's Disease | 3 Participants |
| No Back Pain | Number of Participants Using Vedolizumab for Crohn's Disease | 4 Participants |
Secondary
Number of Participants Using Vedolizumab for Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants Using Vedolizumab for Crohn's Disease | 0 Participants |
| No Back Pain | Number of Participants Using Vedolizumab for Crohn's Disease | 7 Participants |
Secondary
Number of Participants Who Have Had Surgery Related to Crohn's Disease
Time frame: one study visit
Population: The number of participants here only adds up to 31, instead of 33, because data was not collected or lost for two participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants Who Have Had Surgery Related to Crohn's Disease | 10 Participants |
| No Back Pain | Number of Participants Who Have Had Surgery Related to Crohn's Disease | 9 Participants |
Secondary
Number of Participants Who Have Had Surgery Related to Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants Who Have Had Surgery Related to Crohn's Disease | 3 Participants |
| No Back Pain | Number of Participants Who Have Had Surgery Related to Crohn's Disease | 16 Participants |
Secondary
Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 1 quadrant affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | 10 Participants |
| No Back Pain | Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | 1 Participants |
| Fat Metaplasia | Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | 2 Participants |
| Backfill | Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | 1 Participants |
| Ankylosis | Number of Participants With ≥1 Quadrant Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 2 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | 7 Participants |
| No Back Pain | Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥2 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 3 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | 5 Participants |
| No Back Pain | Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥3 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 4 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | 2 Participants |
| No Back Pain | Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥4 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 5 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | 2 Participants |
| No Back Pain | Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥5 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 6 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| No Back Pain | Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥6 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions
MRIs were independently read and scored by 2 expert rheumatologists and 1 newly trained rheumatologist reader, blinded to any clinical information. MRIs were evaluated and scored for presence of bone marrow edema (BME) and structural lesions (erosion, fat metaplasia, backfill and ankylosis) using a validated scoring method originally derived from the Spondyloarthritis Research Consortium of Canada SIJ module. Readers determined whether BME and the structural lesions were present in each of the quadrants for each participant. There are 2 sacroiliac joints and 4 quadrants for each joint, for a total of 8 quadrants for each participant. A quadrant is deemed affected if concordantly reported by ≥ 2/3 readers.
Time frame: one study visit
Population: These Arms/Groups indicate which specific lesion is being looked at in the MRIs by the readers. Each of the 33 participants in the trial had their MRIs looked at for each of the lesions, therefore the overall number of participants analyzed is 33 for each Arm/Group. The count of participants indicates how many participants had at least 7 quadrants affected by a given lesion.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| No Back Pain | Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Fat Metaplasia | Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | 1 Participants |
| Backfill | Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | 0 Participants |
| Ankylosis | Number of Participants With ≥7 Quadrants Affected by BME or Structural Lesions | 2 Participants |
Secondary
Number of Participants With a History of Dactylitis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a History of Dactylitis | 2 Participants |
| No Back Pain | Number of Participants With a History of Dactylitis | 1 Participants |
Secondary
Number of Participants With a History of Peripheral Arthritis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a History of Peripheral Arthritis | 16 Participants |
| No Back Pain | Number of Participants With a History of Peripheral Arthritis | 6 Participants |
Secondary
Number of Participants With a History of Peripheral Arthritis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a History of Peripheral Arthritis | 4 Participants |
| No Back Pain | Number of Participants With a History of Peripheral Arthritis | 18 Participants |
Secondary
Number of Participants With a History of Uveitis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a History of Uveitis | 1 Participants |
| No Back Pain | Number of Participants With a History of Uveitis | 3 Participants |
Secondary
Number of Participants With a Past History of Biologic Use for Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a Past History of Biologic Use for Crohn's Disease | 3 Participants |
| No Back Pain | Number of Participants With a Past History of Biologic Use for Crohn's Disease | 4 Participants |
Secondary
Number of Participants With a Prior History of Biologic Use for Crohn's Disease
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With a Prior History of Biologic Use for Crohn's Disease | 3 Participants |
| No Back Pain | Number of Participants With a Prior History of Biologic Use for Crohn's Disease | 16 Participants |
Secondary
Number of Participants With Axial Spondyloarthritis Based on European Spondyloarthropathy Study Group (ESSG) Guidelines
Assessment of SpondyloArthritis international Society criteria was utilized to define inflammatory back pain.
Time frame: one study visit
Population: There is not another Arm with No Back Pain because this analysis was not done on any patients who identified as having no back pain, since back pain is the primary symptom of axial spondyloarthritis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With Axial Spondyloarthritis Based on European Spondyloarthropathy Study Group (ESSG) Guidelines | 13 Participants |
Secondary
Number of Participants With Current Enthesitis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With Current Enthesitis | 1 Participants |
| No Back Pain | Number of Participants With Current Enthesitis | 8 Participants |
Secondary
Number of Participants With Current Peripheral Arthritis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With Current Peripheral Arthritis | 14 Participants |
| No Back Pain | Number of Participants With Current Peripheral Arthritis | 4 Participants |
Secondary
Number of Participants With Current Peripheral Arthritis
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With Current Peripheral Arthritis | 3 Participants |
| No Back Pain | Number of Participants With Current Peripheral Arthritis | 15 Participants |
Secondary
Number of Participants With HLA-B27 (Human Leukocyte Antigen B-27)
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With HLA-B27 (Human Leukocyte Antigen B-27) | 0 Participants |
| No Back Pain | Number of Participants With HLA-B27 (Human Leukocyte Antigen B-27) | 1 Participants |
Secondary
Number of Participants With Inflammatory Back Pain
Time frame: one study visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Any Back Pain | Number of Participants With Inflammatory Back Pain | 4 Participants |
| No Back Pain | Number of Participants With Inflammatory Back Pain | 15 Participants |
Secondary
TNF-α (Tumor Necrosis Factor)
Concentration of TNF-α in peripheral blood of participants.
Time frame: one study visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Any Back Pain | TNF-α (Tumor Necrosis Factor) | 19.5 pg/mL | Standard Deviation 15.2 |
| No Back Pain | TNF-α (Tumor Necrosis Factor) | 35.4 pg/mL | Standard Deviation 94.1 |